Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nutrition assessment and MASH severity in children using the Healthy Eating Index.
Jain AK, Buchannan P, Yates KP, Belt P, Schwimmer JB, Rosenthal P, Murray KF, Molleston JP, Scheimann A, Xanthakos SA, Behling CA, Hertel P, Nilson J, Neuschwander-Tetri BA, Tonascia J, Vos MB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Jain AK, et al. Hepatol Commun. 2023 Dec 7;7(12):e0320. doi: 10.1097/HC9.0000000000000320. eCollection 2023 Dec 1. Hepatol Commun. 2023. PMID: 38055641 Free PMC article.
The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance.
Gill RM, Allende D, Belt PH, Behling CA, Cummings OW, Guy CD, Carpenter D, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Van Natta ML, Wilson LA, Yamada G, Yeh M, Kleiner DE; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Gill RM, et al. Hepatol Commun. 2023 Feb 1;7(2):e0033. doi: 10.1097/HC9.0000000000000033. eCollection 2023 Feb 1. Hepatol Commun. 2023. PMID: 36724127 Free PMC article.
Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
Newton KP, Jayasekera D, Blackford AL, Behling C, Wilson LA, Fishbein MH, Molleston JP, Xanthakos SA, Vos MB, Schwimmer JB; NASH CRN. Newton KP, et al. Among authors: behling c. Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001216. Online ahead of print. Hepatology. 2025. PMID: 39773889
MASLD: What We Have Learned and Where We Need to Go-A Call to Action.
Hosseini Shabanan S, Martins VF, Wolfson T, Weeks JT, Ceriani L, Behling C, Chernyak V, El Kaffas A, Borhani AA, Han A, Wang K, Fowler KJ, Sirlin CB. Hosseini Shabanan S, et al. Among authors: behling c. Radiographics. 2024 Nov;44(11):e240048. doi: 10.1148/rg.240048. Radiographics. 2024. PMID: 39418184 Review.
Environmental toxicants modulate disease severity in pediatric metabolic dysfunction-associated steatohepatitis.
Jain AK, Busgang SA, Gennings C, Yates KP, Schwimmer JB, Rosenthal P, Murray KF, Molleston JP, Scheimann A, Xanthakos SA, Behling CA, Carpenter D, Fishbein M, Neuschwander-Tetri BA, Tonasia J, Vos MB. Jain AK, et al. Among authors: behling ca. J Pediatr Gastroenterol Nutr. 2024 Nov;79(5):943-953. doi: 10.1002/jpn3.12346. Epub 2024 Sep 16. J Pediatr Gastroenterol Nutr. 2024. PMID: 39282813
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.
Allende DS, Cummings O, Sternberg AL, Behling CA, Carpenter D, Gill RM, Guy CD, Yeh MM, Gawrieh S, Sterling RK, Naggie S, Loomba R, Price JC, McLaughlin M, Hadigan C, Crandall H, Belt P, Wilson L, Chalasani NP, Kleiner DE; HIV NASH and NASH Clinical Research Groups. Allende DS, et al. Among authors: behling ca. Aliment Pharmacol Ther. 2024 Nov;60(10):1351-1360. doi: 10.1111/apt.18236. Epub 2024 Sep 5. Aliment Pharmacol Ther. 2024. PMID: 39238213
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.
Huang DQ, Wilson LA, Behling C, Amangurbanova M, Kleiner DE, Kowdley KV, Dasarathy S, Terrault NA, Diehl AM, Chalasani N, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J, Loomba R; NASH Clinical Research Network. Huang DQ, et al. Among authors: behling c. Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001015. Online ahead of print. Hepatology. 2024. PMID: 39028908
Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology.
Ratziu V, Yilmaz Y, Lazas D, Friedman SL, Lackner C, Behling C, Cummings OW, Chen L, Petitjean M, Gilgun-Sherki Y, Gorfine T, Kadosh S, Eyal E, Sanyal AJ. Ratziu V, et al. Among authors: behling c. Hepatology. 2024 Jun 25. doi: 10.1097/HEP.0000000000000980. Online ahead of print. Hepatology. 2024. PMID: 38916482
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators. Loomba R, et al. Among authors: behling c. N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8. N Engl J Med. 2024. PMID: 38856224 Clinical Trial.
188 results